Literature DB >> 4582633

Inhibition by oxisuran of cell-mediated hypersensitivity by decrease in numbers of specifically sensitized cells.

A E Fox, J L Gingold, H H Freedman.   

Abstract

Oxisuran, 2-([methylsulfinyl]acetyl)pyridine, has previously been shown to selectively suppress cell-mediated immunity, as measured by prolongation of allograft survival, without inhibition of humoral immunity. In the present investigation, the influence of this compound on lymphoid cell transfer of delayed hypersensitivity was studied. In actively sensitized animals, including endotoxin-sensitized mice and rabbits, ovalbumin-, dinitrochlorobenzene-, and dinitrofluorobenzene-sensitive guinea pigs, or tuberculin-sensitive rats, daily treatment during the interval just preceding the elicitation and expression of the hypersensitivity was most inhibitory. In both endotoxin-sensitive mice and ovalbumin-sensitive guinea pigs, treatment of the sensitized cell donor just prior to lymphoid cell harvest and transfer resulted in inhibition of the expression of the hypersensitivity in untreated recipients. Approximately 10(4) fewer specifically sensitized lymphoid cells, but not fewer viable cells, were present in passively transferred cell preparations. In contrast, treatment of the lymphoid cell recipient in the same experimental model did not influence the expression of the transferred hypersensitivity. The results suggest that oxisuran may influence an as yet undefined event prior to the expression of a cell-mediated hypersensitivity response in sensitized animals.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4582633      PMCID: PMC422890          DOI: 10.1128/iai.8.4.549-554.1973

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  7 in total

1.  Role of protein component of endotoxin in modification of host reactivity.

Authors:  H H Freedman; A E Fox; R S Willis; B S Schwartz
Journal:  Proc Soc Exp Biol Med       Date:  1967 Aug-Sep

2.  Oxisuran: a differential inhibitor of cell-mediated hypersensitivity.

Authors:  H H Freedman; A E Fox; J Shavel; G C Morrison
Journal:  Proc Soc Exp Biol Med       Date:  1972-03

3.  Antibody formation at various times after previous treatment of mice with endotoxin.

Authors:  H H Freedman; A E Fox; B S Schwartz
Journal:  Proc Soc Exp Biol Med       Date:  1967-06

4.  Influence of oxisuran, a differential inhibitor of cell-mediated hypersensitivity, on allograft survival and humoral immunity.

Authors:  A E Fox; D L Gawlak; D L Ballantyne; H H Freedman
Journal:  Transplantation       Date:  1973-04       Impact factor: 4.939

5.  Induced sensitization of normal laboratory animals to Brucella abortus endotoxin.

Authors:  H H Freedman; A E Fox; R S Willis; B S Schwartz
Journal:  J Bacteriol       Date:  1968-02       Impact factor: 3.490

6.  Experimental allergic encephalitis. Dissociation of cellular immunity to brain protein and disease production.

Authors:  L E Spitler; C M Von Muller; H H Fudenberg; E H Eylar
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

7.  Delayed hypersensitivity. II. Induction of hypersensitivity in guinea pigs by means of antigen-antibody complexes.

Authors:  A M PAPPENHEIMER; S B SALVIN; J W UHR
Journal:  J Exp Med       Date:  1957-01-01       Impact factor: 14.307

  7 in total
  3 in total

1.  Aldicarb immunomodulation in mice: an inverse dose-response to parts per billion levels in drinking water.

Authors:  L J Olson; B J Erickson; R D Hinsdill; J A Wyman; W P Porter; L K Binning; R C Bidgood; E V Nordheim
Journal:  Arch Environ Contam Toxicol       Date:  1987-07       Impact factor: 2.804

2.  Treponema pallidum infection in subcutaneous polyethylene chambers in rabbits.

Authors:  R R Tight; R L Perkins
Journal:  Infect Immun       Date:  1976-06       Impact factor: 3.441

3.  Comparative activity of CP-17,193 and five established immunosuppressives toward the antigens SRBC and EL4.

Authors:  I G Otterness
Journal:  Clin Exp Immunol       Date:  1981-11       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.